1.685
2.88%
-0.05
After Hours:
1.6712
-0.0138
-0.82%
Ocuphire Pharma Inc stock is currently priced at $1.685, with a 24-hour trading volume of 114.27K.
It has seen a -2.88% decreased in the last 24 hours and a -3.16% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.73 pivot point. If it approaches the $1.69 support level, significant changes may occur.
Previous Close:
$1.735
Open:
$1.75
24h Volume:
114.27K
Market Cap:
$43.68M
Revenue:
$19.05M
Net Income/Loss:
$-9.99M
P/E Ratio:
2.006
EPS:
0.84
Net Cash Flow:
$-1.11M
1W Performance:
-2.03%
1M Performance:
-3.16%
6M Performance:
-42.49%
1Y Performance:
-64.53%
Ocuphire Pharma Inc Stock (OCUP) Company Profile
Name
Ocuphire Pharma Inc
Sector
Industry
Phone
248 681 9815
Address
37000 Grand River Avenue, Suite 120, Farmington Hills
Ocuphire Pharma Inc Stock (OCUP) Latest News
The Market Lifts Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares 42% But It Can Do More - Yahoo Movies Canada
Yahoo Movies Canada
Q2 2024 EPS Estimates for Ocuphire Pharma, Inc. Decreased by HC Wainwright (NASDAQ:OCUP) - Defense World
Defense World
Ocuphire Pharma, Inc. (NASDAQ:OCUP) to Post FY2028 Earnings of $1.74 Per Share, HC Wainwright Forecasts - Defense World
Defense World
Ocuphire Pharma (NASDAQ:OCUP) Raised to Strong-Buy at Canaccord Genuity Group - Defense World
Defense World
Canaccord Genuity Group Lowers Ocuphire Pharma (NASDAQ:OCUP) Price Target to $18.00 - Defense World
Defense World
Ocuphire Pharma (NASDAQ:OCUP) Rating Reiterated by HC Wainwright - Defense World
Defense World
Ocuphire Pharma Inc Stock (OCUP) Financials Data
Ocuphire Pharma Inc (OCUP) Revenue 2024
OCUP reported a revenue (TTM) of $19.05 million for the quarter ending December 31, 2023.
Ocuphire Pharma Inc (OCUP) Net Income 2024
OCUP net income (TTM) was -$9.99 million for the quarter ending December 31, 2023, a -155.83% decrease year-over-year.
Ocuphire Pharma Inc (OCUP) Cash Flow 2024
OCUP recorded a free cash flow (TTM) of -$1.11 million for the quarter ending December 31, 2023, a -107.77% decrease year-over-year.
Ocuphire Pharma Inc (OCUP) Earnings per Share 2024
OCUP earnings per share (TTM) was -$0.48 for the quarter ending December 31, 2023, a -163.16% decline year-over-year.
About Ocuphire Pharma Inc
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
Cap:
|
Volume (24h):